单位：[1]Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室眼科眼科首都医科大学附属北京友谊医院[2]Department of Radiation Oncology, University of California, San Francisco, California, USA[3]Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室肿瘤中心肿瘤内科首都医科大学附属北京友谊医院[4]Multidisciplinary Clinic Center of Ocular Vascular Disease, College of Optometry, Capital Medical University, Beijing, China
Background: Immune checkpoint inhibitors (ICIs) -induced adverse events (AEs) have been reported affecting almost all human organs. However, studies about ocular AEs are few. A meta-analysis was performed to evaluate the risks of ICI-related ophthalmic AEs compare to chemotherapy. Methods: Eligible studies were selected from phase II/III randomized controlled trials investigating ICIs. The data were analyzed by R software and Stata. Results: Odds ratio of treatment-related AE (trAEs) and nonspecific ophthalmic trAEs (NS-trAEs) were lower for PD-1/PD-L1 inhibitors than chemotherapy (OR 0.44, p < .05; OR 0.28, p < .001; OR 0.18, p < . 05; OR: 0.18, p < .001respectively). Compared with monotherapy, PD-1 plus CTLA-4 inhibitors increased the risks of immune-related AEs (irAEs) (OR 4.52, p < .01); ICIs plus chemotherapy increased the risks of trAEs and irAEs (OR 2.82, p < .001; OR 3.63, p < .05 respectively). Conclusions: PD-L1/PD-1 inhibitors had lower risks of trAEs and NS-trAEs than chemotherapy; Compared with monotherapy, combination therapy had higher risks of ophthalmic trAEs and irAEs.
基金：
Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of EducationBeijing Natural Science Foundation [KZ202010025047]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [92046015]
第一作者单位：[1]Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China[3]Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China[4]Multidisciplinary Clinic Center of Ocular Vascular Disease, College of Optometry, Capital Medical University, Beijing, China[*1]Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China[*2]Multidisciplinary clinic center of ocular vascular disease, college of optometry, Capital Medical University, Beijing 100050, China
推荐引用方式(GB/T 7714)：
Hou Yan-Li,Wang Di-Ya,Hu Jie-Xuan,et al.Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis[J].OCULAR IMMUNOLOGY and INFLAMMATION.2021,doi:10.1080/09273948.2021.1890133.
APA：
Hou, Yan-Li,Wang, Di-Ya,Hu, Jie-Xuan,Tian, Ru-Yue,Wang, Wei...&Wang, Yan-Ling.(2021).Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.OCULAR IMMUNOLOGY and INFLAMMATION,,
MLA：
Hou, Yan-Li,et al."Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis".OCULAR IMMUNOLOGY and INFLAMMATION .(2021)
